Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | abTCD haploidentical HSCT in pediatric AL: long-term outcomes

Annalisa Ruggeri • 7 Dec 2019
ASH 2019
Acute Lymphoblastic Leukemia Leukemia

Annalisa Ruggeri, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, outlines the follow-up analysis of the long-term outcome of children with acute leukemia (AL) given alpha-beta T and B-cell depleted HLA-haploidentical hematopoietic stem cell transplantation (TBdepl-haploHSCT). Data from this follow-up confirms in a larger population that TBdepl-haploHSCT is a safe and effective transplant option, being associated with a low risk of both non-relapse mortality and acute/chronic GvHD. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Annalisa Ruggeri

4:55
EBMT 2020: cellular therapy day
Annalisa Ruggeri • 31 Aug 2020
10:00
Graft failure after unmanipulated haplo-HSCT with PT-Cy in AML
Annalisa Ruggeri • 26 Aug 2020
3:39
HSCT with T-cell add-back of rivogenlecleucel in acute leukemia
Annalisa Ruggeri • 7 Dec 2019
2:00
Association of HLA matching with outcome of UD-HSCT: EBMT study
Annalisa Ruggeri • 7 Dec 2019

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals